Want to see HK:8372 full AI Analyst Report?
Top Page
Grand Brilliance Group Holdings Limited
(8372)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$0.17
▲(43.33% Upside)
Action:Downgraded
Date:12/09/25
The stock is supported by strong financial performance and a solid valuation, with a reasonable P/E ratio and dividend yield. However, technical indicators suggest caution due to overbought conditions. The lack of earnings call and corporate events data limits further insights.
Positive Factors
Revenue Growth
The company exhibits strong top-line expansion (reported ~27.9% revenue growth and a 14.78% increase in the latest year), indicating sustained demand and improved market penetration. Durable revenue momentum supports reinvestment, margin leverage and multi-quarter earnings stability.
Negative Factors
Free Cash Flow Decline
A steep 87% drop in free cash flow growth and very low operating cash flow to net income ratio (0.072) signal weak cash conversion of reported earnings. This durable cash generation shortfall can constrain capex, working capital flexibility and dividend/special distribution capacity over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The company exhibits strong top-line expansion (reported ~27.9% revenue growth and a 14.78% increase in the latest year), indicating sustained demand and improved market penetration. Durable revenue momentum supports reinvestment, margin leverage and multi-quarter earnings stability.
Read all positive factors
Grand Brilliance Group Holdings Limited (8372) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$123.20M
Dividend Yield1.62%
Average Volume (3M)226.67K
Price to Earnings (P/E)11.7
Beta (1Y)0.11
Revenue Growth6.63%
EPS Growth-11.02%
CountryHK
Employees51
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.01
Shares Outstanding800,000,000
10 Day Avg. Volume116,000
30 Day Avg. Volume226,666
Financial Highlights & Ratios
PEG Ratio-1.13
Price to Book (P/B)0.89
Price to Sales (P/S)1.04
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Grand Brilliance Group Holdings Limited Business Overview & Revenue Model
Company Description
Grand Brilliance Group Holdings Limited, an investment holding entity, primarily operates by distributing medical equipment and related items across Hong Kong. Its extensive product portfolio encompasses various medical supplies, including disposa...
How the Company Makes Money
null...
Grand Brilliance Group Holdings Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
60
Neutral
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 100.71M | 94.45M | 81.90M | 76.70M | 71.98M |
| Gross Profit | 43.80M | 45.72M | 41.94M | 39.51M | 36.35M |
| EBITDA | 9.34M | 13.95M | 13.20M | 14.09M | 9.87M |
| Net Income | 8.41M | 9.46M | 7.86M | 7.56M | 4.05M |
Balance Sheet | |||||
| Total Assets | 134.70M | 132.19M | 114.50M | 115.25M | 110.32M |
| Cash, Cash Equivalents and Short-Term Investments | 54.19M | 60.96M | 60.47M | 61.86M | 55.74M |
| Total Debt | 2.05M | 3.91M | 1.43M | 4.45M | 4.48M |
| Total Liabilities | 17.15M | 20.75M | 11.22M | 16.58M | 16.82M |
| Stockholders Equity | 117.20M | 110.79M | 103.33M | 98.67M | 93.51M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | 1.17M | 4.91M | 12.60M | -4.12M |
| Operating Cash Flow | 0.00 | 1.35M | 6.72M | 12.66M | -3.33M |
| Investing Cash Flow | 0.00 | 3.77M | -395.00K | -510.00K | -3.96M |
| Financing Cash Flow | 0.00 | -4.87M | -7.42M | -6.40M | -7.58M |
Grand Brilliance Group Holdings Limited Technical Analysis
Positive
0.12
Price Trends
0.14
Positive
0.14
Positive
0.13
Positive
Market Momentum
<0.01
Negative
58.52
Neutral
58.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8372, the sentiment is Positive. The current price of 0.12 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.14, and below the 200-day MA of 0.13, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.52 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8372.
Grand Brilliance Group Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$5.19B | 13.03 | 7.00% | 4.48% | 6.47% | 8.10% | |
70 Outperform | HK$594.00M | 10.93 | 7.70% | 6.25% | 14.28% | 0.81% | |
68 Neutral | HK$123.20M | 11.67 | 9.25% | 1.62% | 6.63% | -11.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$450.82M | -6.31 | -273.18% | ― | 5.52% | 56.54% | |
37 Underperform | HK$851.28M | -9.36 | -2.60% | 17.10% | -2.55% | -145.60% |
* Healthcare Sector Average
HK:8372
Grand Brilliance Group Holdings Limited
0.15
0.05
41.28%
HK:0673
China Health Group
0.31
-0.15
-32.61%
HK:1931
IVD Medical Holding Limited
0.51
-9.89
-95.10%
HK:2192
Medlive Technology Co., Ltd.
7.01
-6.29
-47.31%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.50
-0.18
-3.15%
HK:2427
Guanze Medical Information Industry (Holding) Co., Ltd.
2.39
1.91
397.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.